Model-Based Meta-Analysis (MBMA) for Relative Treatment Effects and Absolute Outcomes: A Focus on Concepts and Applications
2025 年 5 月 27 日 - 11am ET
Danielle Pillsbury2025 年 4 月 10 日
Model-Based Meta-Analysis for All Phases of Drug Development: Capturing the Full Potential of Published Clinical Trial Outcomes [APAC Webinar]
2025 年 5 月 29 日 - 10am Japan/Korea, 9am in China
Danielle Pillsbury2025 年 4 月 3 日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
Danielle Pillsbury2025 年 1 月 9 日
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease
The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…
Danielle Pillsbury2025 年 1 月 8 日
Using MBMA to run virtual “head-to-head trials”
Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…
Danielle Pillsbury2023 年 4 月 21 日
A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease
New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…
Jim Gallagher2021 年 12 月 15 日
Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development
Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…
Leticia Arrington2019 年 12 月 19 日
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond
Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…
Jieun Choe2018 年 6 月 2 日
